ストックスクリーナーアプリを入手
53.38
0.78%
-0.42
プレマーケット:
53.01
-0.37
-0.69%
Travere Therapeutics Inc (TVTX) 最新ニュース
TVTX Maintained by Citigroup -- Price Target Raised to $70.00 - GuruFocus
Travere Therapeutics price target raised to $70 from $62 at Citi - TipRanks
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
TVTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now? - Insider Monkey
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
TVTX Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $65 - GuruFocus
Travere Therapeutics (TVTX) Gets a Buy from Wells Fargo - The Globe and Mail
Roy Baynes to sell 4,500 TVTX shares via option exercise (TVTX) - Stock Titan
TVTX (NASDAQ: TVTX) Form 144 reports 3,250-share sale - Stock Titan
Travere Stock At 20-Year High, Leads 21 Newcomers To Best Stock Lists Like Big Cap 20 - Investor's Business Daily
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Enidnews.com
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
Travere Therapeutics stock hits 52-week high at 48.7 USD By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 48.7 USD - Investing.com
3 Stocks That May Be Priced Below Their Estimated Value In June 2026 - simplywall.st
Travere Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Discipline and Rules-Based Execution in TVTX Response - Stock Traders Daily
Travere therapeutics CCO sells $101,417 in stock for tax obligations - Investing.com
Travere therapeutics chief research officer Rote sells $121,433 in shares - Investing.com
Travere inks licensing deal worth up to $1.1B with China’s Everest Medicines - MSN
Travere buys BTK inhibitor for $1.1bn to treat kidney disease - BioXconomy
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion - ANTARA News
Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines - BioPharma APAC
Travere Therapeutics (TVTX) Rises 2.72% as Stock Nears Key Resistance LevelAdaptive Moving Average - newsline.com
Travere Therapeutics, Inc. (TVTX) Stock: Phase 3 Extension Results Highlight Durable Proteinuria Reduction - parameter.io
Travere Therapeutics, Everest Medicines Partner to Advance Civorebrutinib - Contract Pharma
Travere Therapeutics CFO Cline sells $115,368 in company stock - Investing.com
Why is Travere Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Travere presents five-year FILSPARI data for rare kidney disease By Investing.com - Investing.com Australia
Travere Therapeutics (TVTX) Releases Promising Phase 3 Study Res - GuruFocus
Travere presents five-year FILSPARI data for rare kidney disease - Investing.com
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress - The AI Journal
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63 - Business Wire
Everest Medicines signs $1 B deal with Travere Therapeutics for rare kidney diseases treatment - BioSpectrum Asia
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Guggenheim Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
TVTX Maintained by Citigroup -- Price Target Raised to $62 - GuruFocus
TVTX Reiterated by Wedbush -- Price Target Maintained at $55 - GuruFocus
TVTX: Portfolio expands with civorebrutinib and FILSPARI growth; key clinical catalysts ahead - TradingView
Everest Meds strikes licensing pact with Travere - The Pharma Letter
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases - Macau Business
EVEREST MED (01952.HK) Signs Exclusive License and Collaboration Agreement with Travere Therapeutics, Inc. (TVTX.US), to Receive USD112.5M Upfront Payment - AASTOCKS.com
TVTX Maintained by HC Wainwright & Co. -- Price Target Raised to $67 - GuruFocus
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Yahoo Finance
Travere licenses kidney disease drug from Everest Medicines By Investing.com - Investing.com India
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):